Tag: RNAi therapeutic
Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More
Alnylam all set for givosiran phase 3 acute hepatic porphyrias trial
Clinical trial news : Alnylam Pharmaceuticals said that it has wrapped up enrollment of patients for a phase 3 trial called ENVISION for evaluating givosiran ... Read More